{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=2&page=23", "query": { "intervention": "2", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 3309, "total_pages": 331, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=2&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=2&page=22&page_size=10" }, "source": "local", "last_synced_at": "2026-10-24T03:27:40.074Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05206877", "title": "Topical Insulin for Glaucoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glaucoma" ], "interventions": [ { "name": "Insulin, 20 units", "type": "DRUG" }, { "name": "Insulin, 4 units", "type": "DRUG" }, { "name": "insulin, 20 units three times daily", "type": "DRUG" }, { "name": "insulin, 20 units twice daily", "type": "DRUG" }, { "name": "insulin, 4 units three times daily", "type": "DRUG" }, { "name": "insulin, 4 units twice daily", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2022-04-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-21T12:20:09.737Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05206877" }, { "nct_id": "NCT04703166", "title": "Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy.", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Samsung Galaxy Watch Active2", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Tulane University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 98, "start_date": "2025-04-08", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-21T19:39:59.398Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04703166" }, { "nct_id": "NCT07871435", "title": "GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "GI-102", "type": "DRUG" }, { "name": "Pasritamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GI Innovation, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 107, "start_date": "2026-10-12", "completion_date": "2029-09-30", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-19T12:12:55.952Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07871435" }, { "nct_id": "NCT07766005", "title": "A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa (HS)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "SPY072", "type": "DRUG" }, { "name": "bimekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spyre Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 150, "start_date": "2026-09", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-19T16:17:12.103Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Rogers, Arkansas • Irvine, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07766005" }, { "nct_id": "NCT07752823", "title": "GUT-FEELINGS: Using Citizen Science for Large-Scale Prebiotic Clinical Trials for Mental Wellness in Adults", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Feeling Anxious", "Sleep Disturbance", "Stress" ], "interventions": [ { "name": "Active Gut Feeling Product 1", "type": "OTHER" }, { "name": "Active Gut Feeling Product 2", "type": "OTHER" }, { "name": "Placebo Gut Feeling Control Product", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Holobiome, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "21 Years to 80 Years" }, "enrollment_count": 1000, "start_date": "2026-08-31", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-19T17:27:26.718Z", "location_count": 1, "location_summary": "Del Mar, California", "locations": [ { "city": "Del Mar", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07752823" }, { "nct_id": "NCT07611110", "title": "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Abiraterone", "type": "DRUG" }, { "name": "Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Deutenzalutamide", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Radium-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 670, "start_date": "2026-05-04", "completion_date": "2030-06-06", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-20T13:26:52.668Z", "location_count": 28, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Duarte, California + 24 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07611110" }, { "nct_id": "NCT07610837", "title": "Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatic Cirrhosis", "Liver Fibrosis" ], "interventions": [ { "name": "AZD2389", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2026-05-07", "completion_date": "2027-07-07", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-24T03:27:40.074Z", "location_count": 20, "location_summary": "Chandler, Arizona • Tucson, Arizona • Jupiter, Florida + 15 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Port Orange", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07610837" }, { "nct_id": "NCT07593391", "title": "An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Phelan-McDermid Syndrome" ], "interventions": [ { "name": "NNZ-2591", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neuren Pharmaceuticals Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "3 Years to 12 Years" }, "enrollment_count": 180, "start_date": "2026-06-08", "completion_date": "2028-11-12", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-19T14:39:22.422Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Glendale, California • San Rafael, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "California" }, { "city": "San Rafael", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chevy Chase", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07593391" }, { "nct_id": "NCT07527650", "title": "Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T2DM", "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "HM15275", "type": "DRUG" }, { "name": "Placebo of HM15275", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hanmi Pharmaceutical Company Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 180, "start_date": "2026-05-18", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-19T13:17:43.216Z", "location_count": 20, "location_summary": "Mesa, Arizona • Santa Clarita, California • DeLand, Florida + 14 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Santa Clarita", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07527650" }, { "nct_id": "NCT07521046", "title": "Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "ropeginterferon alfa- 2b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2026-08-21", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-21T14:45:19.040Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07521046" } ] }